Drug Profile
Blinatumomab - Amgen
Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen; Astellas Pharma; BeiGene; M. D. Anderson Cancer Center; Merck & Co; Micromet Inc; National Cancer Institute (USA); University of British Columbia; University of California, Davis
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase II/III Non-Hodgkin's lymphoma
- Phase II Diffuse large B cell lymphoma; Richter's syndrome
- No development reported Burkitt's lymphoma
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Burkitt's-lymphoma(Refractory metastatic disease, Second-line therapy or greater) in Unknown (IV, Infusion)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, In the elderly, Second-line therapy or greater, In adults) in Australia (IV, Infusion)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, In the elderly, Second-line therapy or greater, In adults) in France (IV, Infusion)